Outlook Therapeutics, Inc. (OTLK) News
Filter OTLK News Items
OTLK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OTLK News Highlights
- OTLK's 30 day story count now stands at 9.
- Over the past 22 days, the trend for OTLK's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about OTLK are VERU, LEE and MD.
Latest OTLK News From Around the Web
Below are the latest news stories about Outlook Therapeutics Inc that investors may wish to consider to help them evaluate OTLK as an investment opportunity.
Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific CongressPivotal Phase 3 data from the NORSE TWO registration trial to be presented by Lawrence Lee, MD, MBBS, FRANZCO, FRACSISELIN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Lawrence Lee, MD, MBBS, FRANZCO, FRACS, Associate Professor of Ophthalmology at the University of Queensland and Director |
When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Become Profitable?With the business potentially at an important milestone, we thought we'd take a closer look at Outlook Therapeutics... |
Analysts Are Bullish on These Healthcare Stocks: Veru (VERU), Outlook Therapeutics (OTLK)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERU – Research Report), Outlook Therapeutics (OTLK – Research Report) and Inventiva (IVA – Research Report) with bullish sentiments. Veru (VERU) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Veru, with a price target of $21.00. The company's shares closed last Monday at $6.07, close to its 52-week low of $4.37. According to TipRanks. |
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate UpdateOutlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first ophthalmic formulation of bevacizumab Commercial launch planning underway Financed through the anticipated approval of the ONS-5010 BLA ISELIN, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced |
Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceLive video webcast presentation on Friday, February 18th at 10:40 AM ET Live video webcast presentation on Friday, February 18th at 10:40 AM ET |
Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial OperationsJoel Prieve brings nearly 20 years of commercial operations expertise and proven track record in sales and account management ISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations. “Outlook Therapeutics is thrilled to |
KWB Wealth Buys SPDR Portfolio S&P 600 Small Cap ETF, SPDR Portfolio Short Term Corporate ...Investment company KWB Wealth (Current Portfolio) buys SPDR Portfolio S&P 600 Small Cap ETF, SPDR Portfolio Short Term Corporate Bond ETF, Cisco Systems Inc, PepsiCo Inc, Prudential Financial Inc, sells WisdomTree Yield Enhanced U.S. |
Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film FestivalISELIN, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that members of management will be presenting at and sponsoring the Telluride Retina Film Festival taking place February 3-5, 2022 in Telluride, Colorado. As part of the event, Outlook Therapeutics will present a corporate overview. To learn |
Outlook Therapeutics Provides a Corporate Update and Business OutlookOutlook Therapeutics advancing first ever ophthalmic formulation of bevacizumab towards new U.S. FDA Biologics License Application (BLA) submission, anticipated this quarterONS-5010 / LYTENAVA™ (bevacizumab-vikg) expected to receive, if approved, 12 years of regulatory exclusivity in the U.S. estimated $13 billion global ophthalmic anti-VEGF marketStrong balance sheet to support the Company’s expected capital needs through the anticipated approval of the ONS-5010 BLA expected in the first calend |
Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks ConferenceLive video webcast presentation on Tuesday, January 25th at 3:00 PM ETISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President & Chief Executive Officer will participate in the Virtual Investor 2022 Top Picks Conference on Tuesday, January 25, 2022 at 3:00 PM |